2Russell P J, Pomley J, Raghavan D. The use of monoclonal antibodies for thediagnosis and therapy of bladder cancer. Br J Urol,1993,71:121～125
3Zimmern P E, Laub D, Leach G E. Fluorescein angiography of the bladder:techniqueand relevance to bladder cancer and interstitial cystitis patients. J Urol,1995,154:62～65
4Kriegmair M,Baumgartner R, Knuechel R, et al. Detection of early bladder cancer by5-aminolae-vulinic acid induced porphyrin fluorescence. J Urol,1996,155:105～109
5Wheeless L L,Badalament R A,deVere White,et al.Consensus review of the clinicalutility of DNA cytometry in bladder cancer. Report of the DNA cytometry consensusconference. Cytometry,1993,14:478～481
6Planz B,Striepecke E,Jakse G, et al. Use of lewis X antigen and dexyribonucleic andimage cytometry to increase sensitivity of urinary cytology in transitional cell carcinomaof the bladder. J Urol,1998,159:384～387
6Mehta P.Potential role of platelets in the pathogenesis of tumor metastasis.Blood.1984.63:53.
7Duffy MJ.Reilly D.O'Sullivan C,et al.Urokinase-plasminogen activator,a new and independent prognostic marker in breast cancer.Cancer Res,1990.50:6872.
8Grondahl-Hansen J,Christensen IJ,Rosenquist C,et al.High levels of urokinase-type plasminogen activator and its inhibitor PAL-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.Cancer Res.1993.53:2513.
9Schmalfeldt B,Kuhn W.Reuning U,et al.Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator,its receptor.and inhibitors type 1 and 2.Cancer Res.1995.55:3958.
10Pedersen H,Grondahl-Hansen J.Francis D,et al.Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.Cancer Res,1994.54:120.
